TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Iradimed ( (IRMD) ) has provided an announcement.
On June 19, 2025, Iradimed Corporation held its Annual Meeting of Stockholders, where several key decisions were made. Stockholders elected five directors to the Board, ratified RSM US LLP as the independent auditor for 2025, and approved an advisory resolution on executive compensation. These outcomes reflect shareholder support for the company’s leadership and strategic direction, potentially impacting its governance and operational oversight.
The most recent analyst rating on (IRMD) stock is a Buy with a $72.00 price target. To see the full list of analyst forecasts on Iradimed stock, see the IRMD Stock Forecast page.
Spark’s Take on IRMD Stock
According to Spark, TipRanks’ AI Analyst, IRMD is a Outperform.
Iradimed’s overall stock score is driven by its strong financial performance and optimistic earnings call, reflecting robust growth and strategic positioning in the medical devices market. While technical indicators support positive momentum, valuation concerns with a high P/E ratio and moderate dividend yield suggest careful consideration. Potential risks from international sales and tariff impacts are noted but currently well managed.
To see Spark’s full report on IRMD stock, click here.
More about Iradimed
Iradimed Corporation operates in the medical device industry, specializing in the development and manufacturing of MRI-compatible medical devices. The company focuses on providing innovative solutions to enhance patient care and safety in MRI environments.
Average Trading Volume: 39,467
Technical Sentiment Signal: Strong Buy
Current Market Cap: $740.5M
Find detailed analytics on IRMD stock on TipRanks’ Stock Analysis page.